Skip to main content

What Differentiates Abemaciclib, Ribociclib, and Palbociclib?

Videos — December 9, 2017
Hope S. Rugo, MD
Professor of Medicine and Winterhof Family Professor of Breast Oncology
University of California San Francisco Comprehensive Cancer Center
San Francisco, CA

Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer.

Related Items